|
|
Leukemia Studies Currently Recruiting Participants at the Simmons Cancer Research Center at Southern Illinois University School of Medicine
| Protocol Title |
Study # |
Study Group |
| A Phase I/II Study of CLOLAR® (Clofarabine, IND# 73, 789) in Combination With Cytarabine in Pediatric Patients With Refractory/Relapsed Leukemia |
COG AAML0523 |
SIU COG |
| Accute Myeloid Leukemia |
| A Phase III Randomized Trial for Patients With de Novo AML Using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD |
COG AAML1031 |
SIU COG |
| A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia |
SWOG S0703 |
CICCOP |
| A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML) |
SWOG S0919 |
CICCOP |
| Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years) |
ECOG E2906 |
CICCOP |
| CLL Previously Untreated |
|
|
| A Randomized Phase II Study of Three Fludarabine / Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia |
ECOG/ CALGB 10404 |
CICCOP |
| ALL |
| Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib: IND# 73969, NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia |
COG AALL0622 |
SIU COG |
| Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) |
SWOG S0805 |
CICCOP |
| ALL Newly Diagnosed |
| Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia |
COG AALL0434 |
SIU COG |
| ALL Relapsed |
|
|
| A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND #58,443) in Combination With Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) |
COG AALL07P1 |
SIU COG |
| A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens |
COGAALL05B1 |
SIU COG |
| Myelodysplastic Syndrome |
| Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment With Lenalidomide (Revlimid®) Alone and in Combination With Epoetin Alfa (Procrit®) in Subjects With Low- or Intermediate-1 Risk MDS and Symptomatic Anemia |
ECOG E2905 |
CICCOP |
Although our objective is to provide an updated listing of available clinical trials please note that a listing here does not guarantee that a trial is open or available to any specific patient and that there may be additional trials available that are not listed. Complete information is only available from a treating physician.
Contact Information:
Simmons Cancer Institute Clinical Trials Office
Mail Code 9677 Fax (217) 545-6823
- Kathy Robinson, PhD,
Director of Clinical Trials
(217) 545-1946
-
Allicent Curry, RN,BSN, OCN
Research Nurse
(217) 545-7929 -
-
-
-
-
SIU Behavioral & Psychosocial Oncology
- Anna Wiggins, MS, LCPC
(217) 545-5408
-
SIU COG
- Carol Peterson, RN, CCRP (217) 545-7377
SIU IM
- Amanda Fogleman, B.S. (217) 545-0592
- Krista Whitlock (217) 545-7750
SIU Thoracic
- Theresa Boley, RN, MSN, APN/FNP-BC, CCRP (217) 545-5000
-
- Cathy Leslie, RN, CCRP (217) 545-8184
- Mary Ray, MS (217) 545-7420
-
RTOG: Radiation Therapy Oncology Group:
- Diana Weyhenmeyer, RN, MA, OCN (217) 544-6464 ext. 45591
CICCOP: Central Illinois Community Clinical Oncology Program
Memorial Medical Center CICCOP Research Contacts:
Treatment/Cancer Control:
- Holly Thomas (217) 788-4178
- Stephanie Allbritton (217) 788-3544
- Brooke Trickey (217) 217-788-3560
- Karen Graber (217) 588-2961
- Chrissy Tucker (217) 788-4444
Sunny Hampsey (217) 788-4233
Back to Open Clinical Trials
|
 |
|
